07.29.15
$5.9 Billion
KEY EXECUTIVES:
Ulf Mark Schneider, CEO, Fresenius Group
Rice Powell, CEO, Fresenius Medical Care
Mats Henriksson, CEO Fresenius Kabi
Ron Kuerbitz, CEO, Fresenius Medical Care North America
Mark Costanzo, President, Renal Therapies Group, Fresenius Medical Care North America
Bill Valle, President, Fresenius Medical Services, Fresenius Medical Care North America
John Ducker, President and CEO, Fresenius Kabi USA
Ken Kucera, VP, Supply Chain, Region North America, Fresenius Kabi USA
Dean A. Gregory, President, Medical Devices, Region North America, Fresenius Kabi USA
NO. OF EMPLOYEES: 216, 275 (Fresenius Group total)
GLOBAL HEADQUARTERS: Bad Homburg, Germany
The Fresenius Group is a global healthcare conglomerate with products and services for dialysis (which is mainly what it’s known for—particularly in the United States), the hospital and the medical care of patients at home.
The parent company consists of four business segments that are responsible for their own operations worldwide: Fresenius Medical Care (dialysis products and services), Fresenius Kabi (products for the therapy and care of chronically and critically ill patients, providing intravenously administered generic drugs, infusion therapies, clinical nutrition, and medical devices for delivery of care), Fresenius Helios (operates clinics and hospitals—Germany’s largest) and Fresenius Vamed (provider of services for planning, constructing and managing healthcare facilities).
It’s true that most of the group’s sales aren’t derived from pure-play medical devices, but enough to account for roughly $5.95 billion of the group’s revenue for fiscal 2014 (ended Dec. 31). Medical technology-related sales included $3.58 billion in dialysis product sales from Fresenius Medical Care, in addition to medical devices/infusion technology and infusion therapies sales from Fresenius Kabi totaling roughly $2.37 billion.
For Fresenius Medical Care, net revenue for the full year 2014 increased by 8 percent to $15.83 billion. Net income for full year 2014 dropped by 6 percent to $1.05 billion compared to $1.11 billion for full year 2013. Sales of dialysis products grew by 3 percent to $3.58 billion Accounting for 66 percent of sales, North America remained Fresenius Medical Care’s largest business region. In 2014, sales in North America grew by 9 percent to $10.5 billion compared to $9.6 billion in 2013. Notably, the Asia-Pacific region grew 23 percent, with $1.36 billion in sales for fiscal 2014.
Sales for the entire Fresenius Group for full year 2014 increased to 23.2 billion euros ($28.2 billion) up 14.3 percent from fiscal 2013. EBITDA (earnings before interest, taxes, depreciation and amortization) was 4.10 billion euros ($4.98 billion), up 5.3 percent from fiscal 2013.
On the medical device side, Fresenius Medical Care launched a new cycler that delivers a peritoneal dialysis (PD) therapy tailored to individual patients’ needs. The device, called Sleep-Safe Harmony was released in Europe.
Dialysis patients have chronic kidney disease in common, but they still differ in many ways—by age, height, weight, stage of illness and residual renal function, etc. All of the differences have an impact on the required treatment. If the treatment is closely tailored to the needs of the individual patient, the patent’s overall feeling of health and wellbeing is increased. Compared with previous models, Sleep-Safe Harmony easier to operate, and makes it possible for more patients to tailor their own treatments, according to the company. PD is a therapy that can be conducted at home, if the patient meets certain medical conditions and is willing to learn how to perform the treatment.
Sleep-Safe Harmony has animations built into the machine’s screen that guide the patient through the procedure, so that the patient is assured that all the treatment steps are being performed as planned. This contributes to the improvement of patient compliance and saves training time. As a result, Fresenius officials claim, the new device strongly supports patients in performing their treatment on their own.
Specifically, adapted automated PD (APD) therapy with Sleep-Safe Harmony enables physicians and nurses to combine sequences of short dwells and small fill volumes with long dwells and large fill volumes and varying glucose concentrations.
Adapted APD is a new way of prescribing PD that optimizes ultrafiltration and clearance within one PD session. Sleep-Safe Harmony enables complete individualization for a fully personalized treatment, as well as guided prescription on the cycler or via online software.
In addition, the Sleep-Safe Harmony cycler offers features aimed at improving patient care. The device’s key features are: a large touch screen with animations guiding through each treatment step; guided prescriptions directly on the device; optimized fluid usage (no extra volume for priming needed); convenient handling through automatic connection and barcode recognition of fluid bags, integrated handles and stored patient information, with more than 12 months capacity of treatment data.
Fresenius Medical Care North America is based in Waltham, Mass. Fresenius Kabi USA is headquartered in Lake Zurich, Ill.
KEY EXECUTIVES:
Ulf Mark Schneider, CEO, Fresenius Group
Rice Powell, CEO, Fresenius Medical Care
Mats Henriksson, CEO Fresenius Kabi
Ron Kuerbitz, CEO, Fresenius Medical Care North America
Mark Costanzo, President, Renal Therapies Group, Fresenius Medical Care North America
Bill Valle, President, Fresenius Medical Services, Fresenius Medical Care North America
John Ducker, President and CEO, Fresenius Kabi USA
Ken Kucera, VP, Supply Chain, Region North America, Fresenius Kabi USA
Dean A. Gregory, President, Medical Devices, Region North America, Fresenius Kabi USA
NO. OF EMPLOYEES: 216, 275 (Fresenius Group total)
GLOBAL HEADQUARTERS: Bad Homburg, Germany
The Fresenius Group is a global healthcare conglomerate with products and services for dialysis (which is mainly what it’s known for—particularly in the United States), the hospital and the medical care of patients at home.
The parent company consists of four business segments that are responsible for their own operations worldwide: Fresenius Medical Care (dialysis products and services), Fresenius Kabi (products for the therapy and care of chronically and critically ill patients, providing intravenously administered generic drugs, infusion therapies, clinical nutrition, and medical devices for delivery of care), Fresenius Helios (operates clinics and hospitals—Germany’s largest) and Fresenius Vamed (provider of services for planning, constructing and managing healthcare facilities).
It’s true that most of the group’s sales aren’t derived from pure-play medical devices, but enough to account for roughly $5.95 billion of the group’s revenue for fiscal 2014 (ended Dec. 31). Medical technology-related sales included $3.58 billion in dialysis product sales from Fresenius Medical Care, in addition to medical devices/infusion technology and infusion therapies sales from Fresenius Kabi totaling roughly $2.37 billion.
For Fresenius Medical Care, net revenue for the full year 2014 increased by 8 percent to $15.83 billion. Net income for full year 2014 dropped by 6 percent to $1.05 billion compared to $1.11 billion for full year 2013. Sales of dialysis products grew by 3 percent to $3.58 billion Accounting for 66 percent of sales, North America remained Fresenius Medical Care’s largest business region. In 2014, sales in North America grew by 9 percent to $10.5 billion compared to $9.6 billion in 2013. Notably, the Asia-Pacific region grew 23 percent, with $1.36 billion in sales for fiscal 2014.
Sales for the entire Fresenius Group for full year 2014 increased to 23.2 billion euros ($28.2 billion) up 14.3 percent from fiscal 2013. EBITDA (earnings before interest, taxes, depreciation and amortization) was 4.10 billion euros ($4.98 billion), up 5.3 percent from fiscal 2013.
On the medical device side, Fresenius Medical Care launched a new cycler that delivers a peritoneal dialysis (PD) therapy tailored to individual patients’ needs. The device, called Sleep-Safe Harmony was released in Europe.
Dialysis patients have chronic kidney disease in common, but they still differ in many ways—by age, height, weight, stage of illness and residual renal function, etc. All of the differences have an impact on the required treatment. If the treatment is closely tailored to the needs of the individual patient, the patent’s overall feeling of health and wellbeing is increased. Compared with previous models, Sleep-Safe Harmony easier to operate, and makes it possible for more patients to tailor their own treatments, according to the company. PD is a therapy that can be conducted at home, if the patient meets certain medical conditions and is willing to learn how to perform the treatment.
Sleep-Safe Harmony has animations built into the machine’s screen that guide the patient through the procedure, so that the patient is assured that all the treatment steps are being performed as planned. This contributes to the improvement of patient compliance and saves training time. As a result, Fresenius officials claim, the new device strongly supports patients in performing their treatment on their own.
Specifically, adapted automated PD (APD) therapy with Sleep-Safe Harmony enables physicians and nurses to combine sequences of short dwells and small fill volumes with long dwells and large fill volumes and varying glucose concentrations.
Adapted APD is a new way of prescribing PD that optimizes ultrafiltration and clearance within one PD session. Sleep-Safe Harmony enables complete individualization for a fully personalized treatment, as well as guided prescription on the cycler or via online software.
In addition, the Sleep-Safe Harmony cycler offers features aimed at improving patient care. The device’s key features are: a large touch screen with animations guiding through each treatment step; guided prescriptions directly on the device; optimized fluid usage (no extra volume for priming needed); convenient handling through automatic connection and barcode recognition of fluid bags, integrated handles and stored patient information, with more than 12 months capacity of treatment data.
Fresenius Medical Care North America is based in Waltham, Mass. Fresenius Kabi USA is headquartered in Lake Zurich, Ill.